COMPOSITION:
Each film-coated tablet contains Pirtobrutinib ……………………………. 50 mg.
INDICATION:
LuciPirto is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
DOSAGE AND USE:
The recommended dosage of LuciPirto is 200 mg orally once daily; swallow whole with water, with or without food. Do not cut, crush, or chew tablets.
STORAGE:
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING:
Keep medicine out of reach of Children. Do not administer LuciPirto during Pregnancy and Lactation.
Reviews
There are no reviews yet.